Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast canceropen access
- Authors
- Im, S. -A.; Gennari, A.; Park, Y. H.; Kim, J. H.; Jiang, Z. -F.; Gupta, S.; Fadjari, T. H.; Tamura, K.; Mastura, M. Y.; Abesamis-Tiambeng, M. L. T.; Lim, E. H.; Lin, C. -H.; Sookprasert, A.; Parinyanitikul, N.; Tseng, L. -M.; Lee, S. -C.; Caguioa, P.; Singh, M.; Naito, Y.; Hukom, R. A.; Smruti, B. K.; Wang, S. -S.; Kim, S. B.; Lee, K. -H.; Ahn, H. K.; Peters, S.; Kim, T. W.; Yoshino, T.; Pentheroudakis, G.; Curigliano, G.; Harbeck, N.
- Issue Date
- Jun-2023
- Publisher
- ELSEVIER
- Keywords
- ESMO; guidelines; Pan-Asian; metastatic breast cancer; treatment
- Citation
- ESMO OPEN, v.8, no.3
- Journal Title
- ESMO OPEN
- Volume
- 8
- Number
- 3
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/88840
- DOI
- 10.1016/j.esmoop.2023.101541
- ISSN
- 2059-7029
- Abstract
- The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer (MBC) was published in 2021. A special, hybrid guidelines meeting was convened by ESMO and the Korean Society of Medical Oncology (KSMO) in collaboration with nine other Asian national oncology societies in May 2022 in order to adapt the ESMO 2021 guidelines to take into account the differences associated with the treatment of MBC in Asia. These guidelines represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with MBC representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). The voting was based on the best available scientific evidence and was independent of drug access or practice restrictions in the different Asian countries. The latter were discussed when appropriate. The aim of these guidelines is to provide guidance for the harmonisation of the management of patients with MBC across the different regions of Asia, drawing from data provided by global and Asian trials whilst at the same time integrating the differences in genetics, demographics and scientific evidence, together with restricted access to certain therapeutic strategies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.